Cargando…

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received ≥2 previous lines of therapy). Intravenous mosunetuzumab was administered with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, Budde, Lihua E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463194/ https://www.ncbi.nlm.nih.gov/pubmed/37067952 http://dx.doi.org/10.1182/bloodadvances.2022009260

Ejemplares similares

P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY
por: Sehn, Laurie H., et al.
Publicado: (2023)

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
por: Budde, Lihua E., et al.
Publicado: (2022)

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY
por: Matasar, M., et al.
Publicado: (2022)

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Cheah, C. Y., et al.
Publicado: (2022)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
por: Olszewski, Adam J., et al.
Publicado: (2023)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Detection of Hepatocyte Growth Factor (HGF) Ligand-c-MET Receptor Activation in Formalin-Fixed Paraffin Embedded Specimens by a Novel Proximity Assay
por: Dua, Rajiv, et al.
Publicado: (2011)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma
por: Sanchez Alvarez, Javier, et al.
Publicado: (2023)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Munakata, Wataru, et al.
Publicado: (2023)

Hematopoietic Cell Transplantation for Older Patients with MDS
por: Shadman, Mazyar, et al.
Publicado: (2014)

Childhood trauma fatality and resource allocation in injury control programs in a developing country
por: Roudsari, Bahman S, et al.
Publicado: (2006)

Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
por: Susilo, Monica E., et al.
Publicado: (2023)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2019)

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
por: Hosseini, Iraj, et al.
Publicado: (2020)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

P1148: REAL WORLD DATA (RWD) AMONG FOLLICULAR LYMPHOMA (FL) PATIENTS IN GERMANY WITH AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY AND COMPARISON WITH CLINICAL DATA FOR MOSUNETUZUMAB
por: Marschner, N., et al.
Publicado: (2022)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma
por: Kim, Eugene, et al.
Publicado: (2022)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES
por: Tam, Constantine, et al.
Publicado: (2023)

Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach
por: Chintalacheruvu, Lakshmi Manogna, et al.
Publicado: (2017)

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021)

Rapid recovery following fulminant meningococcemia complicated by myocarditis in a 15-year-old Nepalese girl: a case report
por: Shrestha, Pratyush, et al.
Publicado: (2013)

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018)

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
por: Yoo, Changhoon, et al.
Publicado: (2014)

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
por: Huang, Huiqiang, et al.
Publicado: (2021)

Recalcitrant lupus miliaris disseminatus faciei improved by cyclosporine monotherapy
por: Kwon, Hyeok-Jin, et al.
Publicado: (2022)

Relapse pattern and prognostic factors for patients with primary CNS lymphoma
por: Suh, Cheolwon, et al.
Publicado: (2012)

Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
por: Garnett, William R, et al.
Publicado: (2009)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Thoracic Outlet Syndrome Following Breast Implant Rupture
por: Mistry, Raakhi, et al.
Publicado: (2015)

Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab
por: Crowhurst, Thomas, et al.
Publicado: (2020)

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kbfevlpe5sa8sbgjduv838p1cu